Keck School Faculty

A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors Cancer Chemother Pharmacol. 2021 04; 87(4):525-532. . View in PubMed

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68. . View in PubMed

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216) Clin Cancer Res. 2021 04 01; 27(7):1967-1973. . View in PubMed

Expression of the luteinizing hormone receptor (LHR) in ovarian cancer BMC Cancer. 2019 Nov 15; 19(1):1114. . View in PubMed

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)Clin Genitourin Cancer. 2019 08; 17(4):241-247. e1. . View in PubMed

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy Cancer. 2019 11 01; 125(21):3853-3863. . View in PubMed

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers Clin Cancer Res. 2019 01 01; 25(1):43-51. . View in PubMed

Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types Biochem Biophys Res Commun. 2018 06 07; 500(3):621-625. . View in PubMed

A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer Clin Genitourin Cancer. 2017 12; 15(6):742-749. . View in PubMed

Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients Prostate. 2016 10; 76(14):1239-56. . View in PubMed

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile CancerClin Genitourin Cancer. 2016 10; 14(5):450-456. e1. . View in PubMed

Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Can Urol Assoc J. 2016 Jan-Feb; 10(1-2):E17-22. . View in PubMed

Effects of luteinizing hormone receptor signaling in prostate cancer cells Prostate. 2015 Feb; 75(2):141-50. . View in PubMed

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression PLoS One. 2015; 10(2):e0117758. . View in PubMed

Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. . View in PubMed

A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. . View in PubMed

Differential effects of RUNX2 on the androgen receptor in prostate cancer: synergistic stimulation of a gene set exemplified by SNAI2 and subsequent invasiveness Cancer Res. 2014 May 15; 74(10):2857-68. . View in PubMed

Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases Urology. 2014 Jan; 83(1):159-65. . View in PubMed

Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. . View in PubMed

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer J Nucl Med. 2013 Aug; 54(8):1195-201. . View in PubMed

LHRH and LHR genotypes and prostate cancer incidence and survival Int J Mol Epidemiol Genet. 2013; 4(4):228-34. . View in PubMed

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer Clin Nucl Med. 2012 Jul; 37(7):637-43. . View in PubMed

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors Expert Opin Investig Drugs. 2012 Jun; 21(6):891-9. . View in PubMed

Immune response to sipuleucel-T in prostate cancer Cancers (Basel). 2012 Apr 18; 4(2):420-41. . View in PubMed

Ethnic differences in neuroendocrine expression in prostate cancer tissue Anticancer Res. 2011 Nov; 31(11):3897-901. . View in PubMed

Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer Maturitas. 2011 Aug; 69(4):296-303. . View in PubMed

Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer Expert Opin Investig Drugs. 2011 Jun; 20(6):769-78. . View in PubMed

Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer Prostate. 2011 Jun 01; 71(8):892-8. . View in PubMed

Advanced prostate cancer: new agents, new questions Oncology (Williston Park). 2011 May; 25(6):509512. . View in PubMed

Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors Am J Clin Oncol. 2011 Feb; 34(1):27-31. . View in PubMed

Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors Curr Drug Deliv. 2011 Jan; 8(1):11-25. . View in PubMed

The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes Prostate. 2010 Nov 01; 70(15):1692-700. . View in PubMed

Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists Clin Cancer Res. 2010 Sep 15; 16(18):4675-80. . View in PubMed

The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo Prostate. 2010 Sep 01; 70(12):1359-70. . View in PubMed

Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer Clin Cancer Res. 2010 Jun 01; 16(11):3028-34. . View in PubMed

Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells Prostate. 2009 Jan 01; 69(1):12-23. . View in PubMed

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. . View in PubMed

A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer BJU Int. 2008 Dec; 102(11):1601-6. . View in PubMed

Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer Prostate. 2008 Oct 01; 68(14):1555-60. . View in PubMed

Diet and prostate cancer risk reduction Expert Rev Anticancer Ther. 2008 Jan; 8(1):43-50. . View in PubMed

Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer Anticancer Res. 2008 Jan-Feb; 28(1B):425-30. . View in PubMed

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. . View in PubMed

Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival Hum Pathol. 2007 Oct; 38(10):1547-52. . View in PubMed

Evolving treatment paradigms for locally advanced and metastatic prostate cancer Expert Rev Anticancer Ther. 2006 Nov; 6(11):1639-51. . View in PubMed

Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells Mol Cell Biol. 2006 Oct; 26(19):7331-41. . View in PubMed

Genistein-induced neuroendocrine differentiation of prostate cancer cells Prostate. 2006 Aug 01; 66(11):1136-43. . View in PubMed

Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer Urology. 2006 Jun; 67(6):1247-52. . View in PubMed

Postchemotherapy residual masses in advanced seminoma: current management and outcomes Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. . View in PubMed

Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines Mol Cancer Ther. 2005 Jul; 4(7):1105-13. . View in PubMed

EphB4 expression and biological significance in prostate cancer Cancer Res. 2005 Jun 01; 65(11):4623-32. . View in PubMed

Ethnic differences in neuroendocrine cell expression in normal human prostatic tissue Urology. 2005 May; 65(5):1008-12. . View in PubMed

Glucose metabolism of human prostate cancer mouse xenografts Mol Imaging. 2005 Apr-Jun; 4(2):91-7. . View in PubMed

Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy Eur J Cancer. 2005 Apr; 41(6):932-40. . View in PubMed

Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results J Urol. 2004 Dec; 172(6 Pt 1):2252-5. . View in PubMed

Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation Prostate. 2004 Nov 01; 61(3):253-9. . View in PubMed

Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation Int J Cancer. 2004 Sep 10; 111(4):508-13. . View in PubMed

A new screening system for proliferation-independent anti-cancer agents Cancer Lett. 2004 Jul 08; 210(1):119-24. . View in PubMed

Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma Clin Nephrol. 2003 Dec; 60(6):395-400. . View in PubMed

FDG PET in suspected recurrent and metastatic prostate cancer Oncol Rep. 2003 Sep-Oct; 10(5):1485-8. . View in PubMed

Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts Cancer Res. 2002 Feb 15; 62(4):986-9. . View in PubMed

Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts Cancer Res. 2001 Sep 01; 61(17):6372-6. . View in PubMed

Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II Cancer. 1998 Mar 01; 82(5):909-17. . View in PubMed

Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice Prostate. 1997 Aug 01; 32(3):164-72. . View in PubMed

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II Eur J Cancer. 1997 Jun; 33(7):1141-8. . View in PubMed

Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma Proc Natl Acad Sci U S A. 1997 May 27; 94(11):5810-3. . View in PubMed

Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin Int J Oncol. 1997 May; 10(5):877-84. . View in PubMed

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone Br J Cancer. 1997; 75(11):1585-92. . View in PubMed

Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH) Int J Oncol. 1996 Dec; 9(6):1099-105. . View in PubMed

Effect of chronic administration of a new potent agonist of GH-RH(1-29)NH2 on linear growth and GH responsiveness in rats Regul Pept. 1996 Sep 16; 65(3):197-201. . View in PubMed

Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats Endocrinology. 1996 Aug; 137(8):3430-6. . View in PubMed

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix Proc Natl Acad Sci U S A. 1996 Mar 19; 93(6):2398-402. . View in PubMed

Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice Int J Cancer. 1996 Mar 15; 65(6):870-4. . View in PubMed

Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone J Natl Cancer Inst. 1995 Dec 06; 87(23):1787-94. . View in PubMed

Terminology for luteinizing hormone-releasing hormone antagonists Fertil Steril. 1995 Jul; 64(1):226. . View in PubMed

Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone Proc Natl Acad Sci U S A. 1995 May 23; 92(11):4872-6. . View in PubMed

Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75) Int J Pept Protein Res. 1995 May; 45(5):410-7. . View in PubMed

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone Proc Natl Acad Sci U S A. 1994 Dec 06; 91(25):12298-302. . View in PubMed

Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo Cancer Res. 1994 Nov 15; 54(22):5895-901. . View in PubMed

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice Br J Cancer. 1994 Nov; 70(5):886-92. . View in PubMed

Treatment with luteinizing-hormone-releasing hormone antagonist sb-75 decreases levels of epidermal growth-factor receptor and its messenger-RNA in ov-1063 human epithelial ovarian-cancer xenografts in nude-mice Int J Oncol. 1994 Nov; 5(5):1031-5. . View in PubMed

Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer Int J Cancer. 1994 Oct 01; 59(1):51-5. . View in PubMed

Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer Cancer Lett. 1994 Sep 30; 85(1):111-8. . View in PubMed

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75 Proc Natl Acad Sci U S A. 1994 Jul 19; 91(15):7090-4. . View in PubMed

Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160 Int J Cancer. 1994 May 15; 57(4):574-80. . View in PubMed

Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone Proc Natl Acad Sci U S A. 1994 Mar 01; 91(5):1701-5. . View in PubMed

Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice Cancer. 1994 Feb 15; 73(4):1229-38. . View in PubMed

Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice Biomed Pharmacother. 1994; 48(10):465-72. . View in PubMed

Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer Cancer Res. 1994 Jan 01; 54(1):169-74. . View in PubMed

Somatostatin receptor expression in lung cancer Eur J Cancer. 1994; 30A(11):1682-7. . View in PubMed

Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice Int J Cancer. 1993 Dec 02; 55(6):963-7. . View in PubMed

Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer Cancer. 1993 Dec 01; 72(11):3263-70. . View in PubMed

Inhibition of growth of the human malignant glioma cell line (U87MG) by the steroid hormone antagonist RU486 J Clin Endocrinol Metab. 1993 Nov; 77(5):1388-92. . View in PubMed

Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice Cancer Lett. 1993 Jul 30; 71(1-3):189-96. . View in PubMed

Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75) J Androl. 1993 May-Jun; 14(3):164-9. . View in PubMed

Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats Int J Pept Protein Res. 1993 Mar; 41(3):246-9. . View in PubMed

Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone Int J Pept Protein Res. 1993 Feb; 41(2):162-8. . View in PubMed

Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals Prostate. 1993; 23(2):165-78. . View in PubMed

Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats Int J Pept Protein Res. 1993 Jan; 41(1):66-73. . View in PubMed

Inhibitory effects of the new bombesin receptor antagonist RC-3095 on the luteinizing hormone release in rats Neuroendocrinology. 1992 Dec; 56(6):831-7. . View in PubMed

Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties Proc Natl Acad Sci U S A. 1992 Nov 01; 89(21):10203-7. . View in PubMed

High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration Regul Pept. 1992 Oct 13; 41(3):185-93. . View in PubMed

Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats Am J Physiol. 1992 Oct; 263(4 Pt 1):E712-7. . View in PubMed

Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats Peptides. 1992 Sep-Oct; 13(5):905-11. . View in PubMed

Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines Cancer Res. 1992 Aug 15; 52(16):4545-7. . View in PubMed

Biological activity and receptor binding characteristics to various human tumors of acetylated somatostatin analogs Proc Soc Exp Biol Med. 1992 May; 200(1):49-56. . View in PubMed

Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi Peptides. 1992 Mar-Apr; 13(2):267-71. . View in PubMed

Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH Breast Cancer Res Treat. 1992; 21(1):35-45. . View in PubMed

Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model Prostate. 1992; 20(4):297-310. . View in PubMed

Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75 Prostate. 1992; 20(3):213-24. . View in PubMed

Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi Int J Pept Protein Res. 1991 Dec; 38(6):593-600. . View in PubMed